MedTrace Logo

SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida

NCT04596579 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1135

Last updated 2022-10-03

No results posted yet for this study

Summary

The overall goal of this study is to understand the immune response (IgG) to SARS-CoV-2 to fill critical knowledge gaps in the natural history of this virus and to inform the development of future infection mitigation efforts. The study team aims to assess the prevalence of circulating IgG antibodies to SARS-CoV-2 and the factors associated with sero-prevalence. These data will be used to estimate the total population that has been exposed to the virus (asymptomatic and symptomatic), the proportion of the population that may be protected by natural immunity, and the proportion that is susceptible. Data obtained from this research will be shared with the Florida Department of Health.

Conditions

  • Coronavirus Infection

Interventions

DIAGNOSTIC_TEST

SARS-CoV-2 Antibody Analysis

10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.

DIAGNOSTIC_TEST

Weck-cel Swab Collection

A Weck-cel swab will be used to collect secretions from the mucosal epithelium

BEHAVIORAL

Web Based Questionnaire

A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.

Sponsors & Collaborators

Principal Investigators

  • Anna R Giuliano, PhD · Moffitt Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-17
Primary Completion
2021-07-25
Completion
2021-07-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04596579 on ClinicalTrials.gov